Medical Device Financings Are Strong; Has M&A Flagged?
Through much of the late 1990s, if it weren't for acquisitions, there'd have been little or no deal activity in medical devices. How quickly these trends have reversed themselves; a handful of deals this month suggest that financings are strong again while acquisitions have dropped off the map.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.